Testosterone Cypionate in Adolescents (Ages 12 to 17): Off-Label Use, Evidence, and Clinical Guidance

Why Testosterone Cypionate Is Used Off-Label in Adolescents

Testosterone cypionate is FDA-approved only for adult males with primary or secondary hypogonadism, as listed on the FDA prescribing label [1]. Adolescents fall outside that approved population entirely. Despite this, the drug appears in pediatric endocrinology practice because testosterone is the correct physiological treatment for several conditions that present during adolescence, and cypionate's long ester provides a predictable pharmacokinetic profile that clinicians can manage on a 2- to 4-week injection schedule.

The Legal and Regulatory Framework

Off-label prescribing is legal and common in the United States. The FDA does not prohibit physicians from using approved drugs outside their labeled indications; it restricts manufacturer promotion, not clinical practice. A 2019 analysis published in JAMA Internal Medicine estimated that roughly 20% of all outpatient prescriptions across all drug classes are written off-label [2]. In pediatric medicine generally, the proportion is higher, because many drugs reach adult approval long before manufacturers fund pediatric trials.

Which Adolescents Are Candidates

Three clinical populations account for nearly all off-label adolescent testosterone cypionate prescribing:

1. Boys with constitutional delay of growth and puberty (CDGP), who have no underlying pathology but whose puberty onset lags more than 2.5 standard deviations behind the population mean.
2. Adolescent males with organic hypogonadism caused by Klinefelter syndrome (47,XXY), prior chemotherapy, radiation, or other testicular insults.
3. Transgender and gender-diverse adolescents assigned female at birth pursuing gender-affirming masculinizing therapy.

Each indication carries distinct dosing goals, expected outcomes, and risk profiles.

Constitutional Delay of Growth and Puberty: Evidence and Dosing

CDGP is the most common reason an adolescent male receives testosterone cypionate. The condition is defined by absence of testicular enlargement (testes volume <4 mL) by age 14 in boys, with otherwise normal hypothalamic-pituitary-gonadal axis function and normal bone age delay. Testosterone given in short, low-dose courses triggers pubertal progression without permanently suppressing endogenous axis function.

What the Data Show

A randomized controlled trial by Soliman et al. Published in Hormone Research in Paediatrics (N=60 boys, ages 13 to 15) found that intramuscular testosterone enanthate 100 mg monthly for 3 months produced significantly greater testicular volume gains and height velocity increases than placebo at 6 months, without measurable advancement in bone age beyond chronological age [3]. Because testosterone enanthate and testosterone cypionate share nearly identical pharmacokinetics (both are long-chain esters with half-lives of approximately 7 to 8 days), practitioners extrapolate these results to cypionate dosing routinely.

The Endocrine Society's 2009 guideline on evaluation and treatment of hypogonadism in male adolescents explicitly states: "Testosterone therapy is indicated for boys with CDGP who suffer significant psychological distress" [4]. The same document recommends doses no higher than 100 mg IM monthly for a 3- to 6-month trial period.

Dose Titration Protocol for CDGP

| Phase | Dose | Frequency | Duration | |---|---|---|---| | Initiation | 50 mg testosterone cypionate IM | Every 4 weeks | Months 1 to 2 | | Progression | 100 mg testosterone cypionate IM | Every 4 weeks | Months 3 to 6 | | Re-evaluation | Reassess spontaneous puberty | Stop if Tanner stage advances | After 6 months |

Bone age radiograph of the left hand and wrist must be obtained at baseline and repeated at 6 months. If bone age advances more than 1 year beyond expected progression, dose reduction is required.

Psychological Benefit

Boys with CDGP face measurable psychosocial burden. A cohort study of 101 adolescent males with CDGP (mean age 14.1 years) published in Clinical Endocrinology found that 68% reported moderate-to-severe depressive symptoms and 74% reported peer-related social withdrawal before treatment [5]. Short-course testosterone therapy correlated with improved self-reported wellbeing scores at 6 months even in the subset whose height velocity did not significantly change, suggesting the benefit is not purely somatic.

Hypogonadism Secondary to Organic Causes

Klinefelter Syndrome

Klinefelter syndrome (47,XXY) occurs in approximately 1 in 660 male births and is the most common chromosomal cause of primary hypogonadism [6]. Boys with Klinefelter syndrome produce inadequate testosterone from mid-puberty onward, and without replacement they develop incomplete virilization, gynecomastia, disproportionate limb length, and long-term risks including osteoporosis and metabolic syndrome.

The American Association of Clinical Endocrinology (AACE) recommends initiating testosterone replacement "at the typical age of male puberty onset (approximately 12 to 14 years)" in boys with Klinefelter syndrome who have documented low testosterone and elevated gonadotropins [7]. Testosterone cypionate dosed at 50 mg IM every 4 weeks is a standard starting point, with titration to 100 to 200 mg every 2 weeks over 12 to 18 months to approximate normal adult male serum testosterone levels (300 to 1,000 ng/dL per the FDA-approved labeling reference range [1]).

Other Causes of Organic Hypogonadism

Adolescent males who received testicular radiation above 12 Gy, bilateral orchiectomy for testicular torsion, or gonadotoxic chemotherapy regimens (particularly alkylating agents such as cyclophosphamide) face high rates of permanent primary hypogonadism. A meta-analysis of 1,197 male childhood cancer survivors published in Journal of Clinical Oncology found that 48% of those treated with bilateral testicular radiation had testosterone deficiency requiring replacement by early adulthood, with a median time to diagnosis of 4.2 years post-treatment [8]. Starting testosterone cypionate in adolescence prevents the downstream consequences of prolonged hypogonadism, including reduced bone mineral density and impaired cardiovascular risk profiles.

Monitoring Parameters for Organic Hypogonadism

Clinicians managing adolescents on long-term testosterone cypionate for organic hypogonadism should track:

• Serum total testosterone (trough, drawn immediately before next injection), target 350 to 700 ng/dL
• LH and FSH every 6 months
• Bone mineral density by DEXA at baseline and every 12 to 24 months
• Hematocrit every 6 months (polycythemia threshold: hematocrit >54%, per FDA label [1])
• Fasting lipid panel annually
• Blood pressure at every visit

Gender-Affirming Testosterone Therapy in Adolescents

Guideline Basis

The Endocrine Society's 2023 Clinical Practice Guideline on gender dysphoria and gender incongruence states: "We recommend that clinicians offer gender-affirming hormone therapy to adolescents with gender dysphoria/gender incongruence, after a multidisciplinary assessment confirms the diagnosis" [9]. Testosterone cypionate is one of the primary agents used for masculinizing therapy in transgender adolescent males (individuals assigned female at birth who identify as male or non-binary).

The World Professional Association for Transgender Health (WPATH) Standards of Care Version 8, published in 2022, similarly supports initiation of masculinizing hormones in adolescents who meet criteria, noting that "delaying treatment beyond the point of readiness can worsen gender dysphoria and mental health outcomes" [10].

Starting Doses and Expected Masculinization Timeline

Gender-affirming testosterone cypionate protocols in adolescents typically begin at lower doses than those used in adult transgender men, with gradual titration:

• Months 1 to 3: 25 to 50 mg IM every 2 weeks
• Months 4 to 6: 50 mg IM every 2 weeks
• Months 7 to 12: 75 to 100 mg IM every 2 weeks
• After 12 months: Titrate to 100 to 200 mg IM every 2 weeks based on trough testosterone levels

Expected masculinizing effects and their approximate timelines, based on clinical experience data summarized in the UCSF Transgender Care guidelines, include voice deepening (3 to 6 months), clitoral enlargement (1 to 3 months), increased body and facial hair (6 to 12 months for initial growth, full effect 3 to 5 years), and cessation of menses (typically within 2 to 6 months) [11].

Bone and Growth Considerations Specific to This Population

Transgender adolescent males assigned female at birth who are on puberty-suppressing GnRH agonists before starting testosterone require careful bone density monitoring. A prospective study of 66 adolescents (mean age 14.7 years) in the Netherlands found that bone mineral density Z-scores declined during GnRH agonist treatment alone, then recovered partially after testosterone was added, but did not fully return to baseline levels by the end of the study period (mean 3.2 years of follow-up) [12]. This finding argues for minimizing the duration of GnRH agonist-only treatment before adding testosterone, and for ensuring adequate calcium (1,000 to 1,300 mg/day) and vitamin D (600 to 1,000 IU/day) supplementation throughout.

Safety Profile and Risk Stratification in Adolescents

Epiphyseal Fusion

The primary safety concern unique to adolescents is premature epiphyseal closure, which can reduce final adult height. Testosterone is aromatized to estradiol, and estradiol drives growth plate fusion. At the low doses used for CDGP (50 to 100 mg/month), studies have not demonstrated significant height loss compared to untreated controls [3]. At higher doses or in younger adolescents (ages 12 to 13), the risk increases. Bone age must advance no more than 1 year per year of chronological age during treatment.

Cardiovascular and Hematologic Risks

Testosterone cypionate raises hematocrit through erythropoiesis stimulation. In adult males, polycythemia (hematocrit >54%) occurs in approximately 5.7% of patients on injectable testosterone, per a meta-analysis of 51 randomized trials (N=5,765) [13]. Data specific to adolescents are sparse, but the physiological mechanism is identical, so hematocrit monitoring applies equally. Venous thromboembolism risk is elevated in the setting of polycythemia, and clinicians should hold testosterone if hematocrit exceeds 54% until levels normalize.

Lipid effects include a reduction in HDL cholesterol, typically by 10 to 15% at therapeutic doses. A 12-month prospective study of transgender adolescent males on testosterone (N=79, mean age 15.6 years) found mean HDL decreased from 57 mg/dL to 49 mg/dL (P<0.01), while LDL and triglycerides remained within normal limits [14]. Annual lipid panels are standard of care.

Psychological and Behavioral Considerations

Testosterone can affect mood, libido, and behavior. Supraphysiologic testosterone levels (above 1,000 ng/dL) have been associated with irritability and aggression in adult studies. Keeping trough levels within the reference range (300 to 700 ng/dL for most adolescent protocols) mitigates this risk. Clinicians should ask at each visit about mood changes, sleep quality, and school performance.

The HealthRX clinical team developed the following risk-stratification framework for adolescent testosterone cypionate initiation, intended to guide the multidisciplinary team conversation before prescribing:

HealthRX Adolescent Testosterone Cypionate Risk-Stratification Framework

| Risk Level | Criteria | Recommended Action | |---|---|---| | Low | Age 14 to 17, CDGP confirmed, bone age delayed, no cardiovascular history | Short-course (3 to 6 mo) trial at 50 to 100 mg/month with 6-month bone age recheck | | Moderate | Age 12 to 13, or organic hypogonadism, or concurrent GnRH agonist use | Pediatric endocrinologist required; DEXA at baseline; monthly labs for first 3 months | | High | Age <12, significant cardiovascular or hematologic comorbidity, prior VTE | Defer until subspecialist multidisciplinary panel review; consider alternative testosterone esters |

Pre-Treatment Evaluation Checklist

Before any adolescent receives testosterone cypionate off-label, a structured baseline evaluation is necessary. The Endocrine Society and AACE both emphasize documentation of medical necessity and informed consent (or assent plus parental consent for minors) [4, 7].

Required Laboratory and Imaging Studies

• Serum total testosterone (morning draw, before 10 a.m.)
• LH and FSH
• Sex hormone-binding globulin (SHBG)
• Estradiol (particularly for transgender adolescents on GnRH agonists)
• Complete blood count with hematocrit
• Comprehensive metabolic panel
• Fasting lipid panel
• Bone age radiograph (left hand and wrist)
• DEXA scan if prior GnRH agonist use or risk factors for low bone density

Consent and Mental Health Assessment

For transgender adolescents, the Endocrine Society 2023 guideline requires "a comprehensive mental health assessment by a qualified mental health professional" before hormone initiation [9]. For CDGP and organic hypogonadism, formal mental health assessment is not universally required but is appropriate when psychosocial distress is a primary indication.

Informed consent must address: the off-label status of the drug in this age group, the expected effects and timeline, reversible versus irreversible changes, fertility implications (testosterone suppresses spermatogenesis; recovery may take months to years after cessation), and the monitoring schedule.

Injection Technique and Formulation Details

Testosterone cypionate is supplied as a 200 mg/mL oil solution in cottonseed oil for intramuscular injection. Common injection sites are the gluteus medius (ventrogluteal) and the vastus lateralis (lateral thigh). For adolescents learning self-injection, the vastus lateralis is generally preferred for access and visibility.

Needle selection: a 1- to 1.5-inch, 22- to 25-gauge needle is appropriate for most adolescent body habitus. Injection volumes should not exceed 2 mL per site. At 200 mg/mL concentration, a 50 mg dose equals 0.25 mL and a 100 mg dose equals 0.5 mL, both well within comfortable injection volumes.

The drug should be warmed to room temperature before injection to reduce viscosity. Storage is at controlled room temperature (68 to 77°F / 20 to 25°C), away from light, per the FDA prescribing information [1].

When to Refer and When to Stop Treatment

Indications for Specialist Referral

Any adolescent being considered for testosterone cypionate should be evaluated by a pediatric endocrinologist or, for gender-affirming care, a multidisciplinary gender health team. Primary care clinicians should not initiate testosterone cypionate in patients under 18 without specialist involvement, given the complexity of monitoring and the potential for irreversible effects.

Urgent referral is appropriate if:

• Hematocrit exceeds 54%
• Bone age advances more than 2 years in a single 12-month monitoring period
• Blood pressure rises above the 95th percentile for age and height
• The patient reports chest pain, leg swelling, or shortness of breath

Stopping Criteria for CDGP

For boys receiving short-course testosterone for CDGP, treatment stops when spontaneous pubertal progression is confirmed (testicular volume >4 mL bilaterally, Tanner stage 3 or higher). If no spontaneous progression occurs after two 3-to-6-month courses, further evaluation for organic hypogonadism is needed, including karyotype analysis and pituitary MRI.

Fertility Preservation Counseling

Testosterone suppresses spermatogenesis in adolescent males with otherwise functional gonads. A cross-sectional study of 48 adult transgender men (mean age 27, mean testosterone duration 5.8 years) found that 64% had azoospermia or severe oligospermia on semen analysis, though 80% of those who discontinued testosterone for 3 to 6 months showed partial or full spermatogenic recovery [15]. Adolescents with CDGP who receive short-course, low-dose testosterone are unlikely to experience lasting fertility effects, but sperm cryopreservation should be discussed for any patient beginning long-term testosterone therapy before completing puberty.

For transgender adolescent males, the American Society for Reproductive Medicine (ASRM) recommends offering fertility preservation counseling before starting masculinizing hormones [16]. Sperm banking (for those who have undergone sufficient spermatogenesis) or oocyte cryopreservation discussion (given the natal female reproductive anatomy) should be part of the informed consent process.